home / stock / ipsef / ipsef short
Short Information | Ipsen Sa Ord (OTCMKTS:IPSEF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 9,107 |
Total Actual Volume | 9,141 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 18 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 455 |
Average Short Percentage | 90.99% |
Is there a IPSEF Short Squeeze or Breakout about to happen?
See the IPSEF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-01-2024 | $0 | $131.1968 | $0 | $0 | 8 | 8 | 100% |
06-14-2024 | $0 | $131.1968 | $0 | $0 | 439 | 439 | 100% |
06-10-2024 | $0 | $131.1968 | $0 | $0 | 1 | 1 | 100% |
05-29-2024 | $0 | $131.1968 | $0 | $0 | 2,236 | 2,236 | 100% |
05-28-2024 | $0 | $132.5 | $0 | $0 | 9 | 9 | 100% |
05-21-2024 | $132.5 | $132.5 | $132.5 | $132.5 | 171 | 171 | 100% |
04-24-2024 | $0 | $117.6 | $0 | $0 | 62 | 62 | 100% |
04-03-2024 | $0 | $117.6 | $0 | $0 | 15 | 15 | 100% |
03-14-2024 | $117.6 | $117.6 | $117.6 | $117.6 | 100 | 100 | 100% |
03-01-2024 | $110.3565 | $110.3565 | $110.3565 | $110.3565 | 1,559 | 1,559 | 100% |
02-29-2024 | $110.5243 | $110.5243 | $110.5243 | $110.5243 | 1,054 | 1,054 | 100% |
02-21-2024 | $111.5 | $111.5 | $111.5 | $111.5 | 100 | 100 | 100% |
02-14-2024 | $0 | $113.25 | $0 | $0 | 22 | 3 | 13.64% |
02-13-2024 | $112.21 | $113.25 | $113.25 | $112.21 | 200 | 200 | 100% |
01-10-2024 | $0 | $117.25 | $0 | $0 | 1,473 | 1,473 | 100% |
01-09-2024 | $0 | $117.25 | $0 | $0 | 16 | 1 | 6.25% |
01-02-2024 | $117.25 | $117.25 | $117.25 | $117.25 | 100 | 100 | 100% |
10-26-2023 | $0 | $117.69 | $0 | $0 | 161 | 161 | 100% |
10-16-2023 | $0 | $117.69 | $0 | $0 | 1,414 | 1,414 | 100% |
09-21-2023 | $0 | $117.69 | $0 | $0 | 1 | 1 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreemen...
Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholan...
Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaboration Research will focus on using Marengo’s TriSTAR platform to reinvigorate and mobilize selective V...